Dr. EVRIM KADRIYE TEZCANLI

Snapshot Highlights

• Over 10 years of dedicated experience in Radiation Oncology.
• Expertise in advanced cancer treatment modalities.
• Extensive publication record in leading oncology journals and congresses.
• Active member of esteemed national and international oncology associations.
• Affiliated with Acıbadem Health Group, a renowned healthcare provider.

Dr. EVRIM KADRIYE TEZCANLI

Professional Experience

Dr. Evrim Kadriye Tezcanlı brings over a decade of specialized experience in Radiation Oncology to her practice. Since 2020, she has been a valued member of the Acıbadem Health Group, contributing her extensive knowledge and skills to patient care. Her career is marked by a consistent commitment to advancing the field through research and clinical practice.

Education

Dr. Tezcanlı’s foundational medical education was completed at Istanbul University Istanbul Faculty of Medicine from 1995 to 2000. She further honed her expertise by specializing in Radiation Oncology at Marmara University Faculty of Medicine, graduating in 2005. Her early academic pursuits included attendance at Gazi Anatolian High School, from 1992 to 1995.

Professional Affiliations and Contributions

Dr. Tezcanlı actively participates in the medical community as a member of the Radiation Oncology Association and the Turkish Oncology Association. These memberships underscore her dedication to staying at the forefront of oncological advancements and collaborative research.

Selected Publications and Research

Dr. Tezcanlı has made significant contributions to the field of oncology through her published research. Her work includes studies on the tolerability and efficacy of temozolomide in gliomas, the characteristics of nasopharynx tumors treated with stereotactic radiosurgery, and chemoradiotherapy outcomes for bladder tumors. She has also explored the prognostic significance of MIB-1 labeling indices and Ki-67 proliferation in oligodendroglial tumors and glioblastoma multiforme. Her research has been presented at prestigious events such as the XVI National Cancer Congress and has appeared in proceedings like those of ASCO.